Pfizer and BioNTech Nab Fast Track Status for Two COVID-19 Vaccines

The FDA has granted Pfizer and BioNTech fast track designations for two messenger RNA-based COVID-19 vaccine candidates.  

The agency granted the designations for BNT162b1 and BNT162b2 based on promising early results from clinical trials in the U.S. and Germany, and on data from animal studies.

Moderna — another frontrunner in the race for an approved COVID-19 vaccine — earned a fast track designation from the FDA for its vaccine candidate mRNA-1273 in May.